[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and",
    "url": "https://finnhub.io/api/news?id=55427c50acf73d92a339e4634b7a6e340df09a2ca208de026695145278b06c45",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768337393,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 138089298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index down 0.5% and",
      "url": "https://finnhub.io/api/news?id=55427c50acf73d92a339e4634b7a6e340df09a2ca208de026695145278b06c45"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Tuesday Afternoon",
    "summary": "Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S",
    "url": "https://finnhub.io/api/news?id=bf2b1443ae5b48f5dbb4d87a4a9040925c4b953508fd3c01891405db23c41578",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768329695,
      "headline": "Sector Update: Health Care Stocks Decline Tuesday Afternoon",
      "id": 138087367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were lower Tuesday afternoon, with the NYSE Health Care Index down 0.6% and the S",
      "url": "https://finnhub.io/api/news?id=bf2b1443ae5b48f5dbb4d87a4a9040925c4b953508fd3c01891405db23c41578"
    }
  },
  {
    "ts": null,
    "headline": "Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight",
    "summary": "The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW",
    "url": "https://finnhub.io/api/news?id=9018a25a2a4615bbb33eb24bd758fac97e29535b9bd1ad45b8fc6d54ce26dedf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768327200,
      "headline": "Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight",
      "id": 138086644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & Johnson), Litifilimab (Biogen and Royalty Pharma), Ianalumab (Novartis), Cenerimod (Idorsia and Viatris), Rapcabtagene autoleucel (YTB323) (Novartis), KK-4277 (Kyowa Kirin), and others, and better diagnostic tools, which might improve the prognosis of the disease.New York, USA, Jan. 13, 2026 (GLOBE NEW",
      "url": "https://finnhub.io/api/news?id=9018a25a2a4615bbb33eb24bd758fac97e29535b9bd1ad45b8fc6d54ce26dedf"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: J&J leans on immunology launches to fuel annual growth",
    "summary": "Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.",
    "url": "https://finnhub.io/api/news?id=70f012f4bec9f956f43fcd86782d22bdd40114c3ad9e0a55f805511d48f26f8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768322573,
      "headline": "JPM26: J&J leans on immunology launches to fuel annual growth",
      "id": 138086645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.",
      "url": "https://finnhub.io/api/news?id=70f012f4bec9f956f43fcd86782d22bdd40114c3ad9e0a55f805511d48f26f8c"
    }
  },
  {
    "ts": null,
    "headline": "Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer",
    "summary": "Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The \"Bipolar Disorder: Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a",
    "url": "https://finnhub.io/api/news?id=3a3be8bfce30960c5d0a724a301e91e201d0fb9c1926dbb97f726033c338007a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768321260,
      "headline": "Bipolar Disorder Market Opportunity Assessment and Forecast Report 2024-2034 Featuring Johnson & Johnson, Otsuka, AbbVie, Bristol Myers-Squibb, OWP, Sumitomo, Pfizer",
      "id": 138086646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Key market opportunities in the Bipolar Disorder market include developing targeted treatments for bipolar depression due to current unmet needs, capitalizing on late-stage pipeline products projected to influence market growth, and leveraging strategic partnerships and emerging players with strong portfolios.Dublin, Jan. 13, 2026 (GLOBE NEWSWIRE) -- The \"Bipolar Disorder: Opportunity Assessment and Forecast\" report has been added to ResearchAndMarkets.com's offering.This report covers the 7MM a",
      "url": "https://finnhub.io/api/news?id=3a3be8bfce30960c5d0a724a301e91e201d0fb9c1926dbb97f726033c338007a"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: J&J reveals oncology strategy",
    "summary": "Oncology is set to play a major role in J&J’s revenue outlook, generating $50bn in sales in 2030.",
    "url": "https://finnhub.io/api/news?id=6c25399345313e68053e7d1939b44e176585ff9b80855e51266f15fc04f30f70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768320773,
      "headline": "JPM26: J&J reveals oncology strategy",
      "id": 138086647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Oncology is set to play a major role in J&J’s revenue outlook, generating $50bn in sales in 2030.",
      "url": "https://finnhub.io/api/news?id=6c25399345313e68053e7d1939b44e176585ff9b80855e51266f15fc04f30f70"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Lifted Johnson & Johnson (JNJ) in Q4",
    "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]",
    "url": "https://finnhub.io/api/news?id=df72fb460efe2292c07a025591a5a67bf3dad617d2476d432f958824cc3e54b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768315547,
      "headline": "Here’s What Lifted Johnson & Johnson (JNJ) in Q4",
      "id": 138084495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its […]",
      "url": "https://finnhub.io/api/news?id=df72fb460efe2292c07a025591a5a67bf3dad617d2476d432f958824cc3e54b2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and transl",
    "url": "https://finnhub.io/api/news?id=248a5bcdf34ed48e57961bd5c1056b95d294553e43cec9fab63929ee7faf9b26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768309200,
      "headline": "Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting",
      "id": 138083193,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today that 11 abstracts featuring new data on its robust portfolio and pipeline in neuropsychiatry will be presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), held from January 12-15, in Nassau, Bahamas. Presentations include the latest research from across the Company's neuropsychiatry portfolio, including major depressive disorder (MDD) and treatment-resistant depression (TRD), as well as preclinical and transl",
      "url": "https://finnhub.io/api/news?id=248a5bcdf34ed48e57961bd5c1056b95d294553e43cec9fab63929ee7faf9b26"
    }
  },
  {
    "ts": null,
    "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
    "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
    "url": "https://finnhub.io/api/news?id=4bbd2e0d05be89da16efff4aa039eb3fbef25f9109658ddf301a26ce3cc78431",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308840,
      "headline": "Inside Pfizer's Oncology Performance Ahead of Q4 Results",
      "id": 138084496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.",
      "url": "https://finnhub.io/api/news?id=4bbd2e0d05be89da16efff4aa039eb3fbef25f9109658ddf301a26ce3cc78431"
    }
  },
  {
    "ts": null,
    "headline": "What's Powering J&J's MedTech Growth Ahead of Q4 Release?",
    "summary": "JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.",
    "url": "https://finnhub.io/api/news?id=f85c3faba5d5edacb66dd7bb56ac9b9e68dfef94d6bd3d8a2ebdf1b63e56dd0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308480,
      "headline": "What's Powering J&J's MedTech Growth Ahead of Q4 Release?",
      "id": 138084497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's MedTech unit is gaining momentum from cardiovascular strength and new products, even as China pressure lingers into the next quarter.",
      "url": "https://finnhub.io/api/news?id=f85c3faba5d5edacb66dd7bb56ac9b9e68dfef94d6bd3d8a2ebdf1b63e56dd0c"
    }
  },
  {
    "ts": null,
    "headline": "J&J adds 2 US manufacturing plants to investment plans",
    "summary": "The pharmaceutical giant said it will build production facilities in North Carolina and Pennsylvania as part of its broader $55 billion investment commitment.",
    "url": "https://finnhub.io/api/news?id=e9d5c3953e0dfc6282b6bb23dcf58a8570c8c485ab3279bb30a276a9dc14421e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768303620,
      "headline": "J&J adds 2 US manufacturing plants to investment plans",
      "id": 138086648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The pharmaceutical giant said it will build production facilities in North Carolina and Pennsylvania as part of its broader $55 billion investment commitment.",
      "url": "https://finnhub.io/api/news?id=e9d5c3953e0dfc6282b6bb23dcf58a8570c8c485ab3279bb30a276a9dc14421e"
    }
  },
  {
    "ts": null,
    "headline": "2 No-Brainer Dividend Stocks to Buy Right Now",
    "summary": "More than 60 straight years of increasing dividends reflects a strong commitment behind these stocks.",
    "url": "https://finnhub.io/api/news?id=17897c4f3d74d5f665d3ca787a0d5d8dc2e994f429aad41715e62b1c19890e63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768300500,
      "headline": "2 No-Brainer Dividend Stocks to Buy Right Now",
      "id": 138083194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "More than 60 straight years of increasing dividends reflects a strong commitment behind these stocks.",
      "url": "https://finnhub.io/api/news?id=17897c4f3d74d5f665d3ca787a0d5d8dc2e994f429aad41715e62b1c19890e63"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
    "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
    "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768299840,
      "headline": "AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs.",
      "id": 138083151,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "AbbVie  has agreed to cut some drug prices and invest $100 billion in the U.S. in exchange for an exemption from some tariffs.  The pharma company said in a statement late Monday that it had struck a deal with the Trump administration to lower Medicaid prices and pour the money into U.S. research and development.  AbbVie will also expand its direct-to-patient offerings of certain drugs on the government portal TrumpRx.",
      "url": "https://finnhub.io/api/news?id=e703854b3b85d22e1a0a8c62c02820a8ea079b07155cfe39db7ccb9a8b6421b7"
    }
  },
  {
    "ts": null,
    "headline": "Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors",
    "summary": "Alphabet, Johnson & Johnson and Danaher Corp. were among the portfolioâs top contributors for the quarter, while Oracle, Microsoft and Linde plc detracted from performance. Read more here.",
    "url": "https://finnhub.io/api/news?id=bbad6bdf70499f68ab9bed4c1136f9a2d94e2baea32daf1e93d755fcf202083a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768272000,
      "headline": "Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors",
      "id": 138081158,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1060242386/image_1060242386.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Alphabet, Johnson & Johnson and Danaher Corp. were among the portfolioâs top contributors for the quarter, while Oracle, Microsoft and Linde plc detracted from performance. Read more here.",
      "url": "https://finnhub.io/api/news?id=bbad6bdf70499f68ab9bed4c1136f9a2d94e2baea32daf1e93d755fcf202083a"
    }
  }
]